Last reviewed · How we verify
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
The present hypothesis is that anti-EGFR agents are active in tumors with low-level RAS mutation when the majority of tumor cells is still sensitive. While response rate may be high and may reflect sensitivity to anti-EGFR agents, PFS is anticipated to be shorter than in RAS wild-type patients due to the faster development of resistance when sensitive cells are eradicated and when the RAS-mutant anti-EGFR resistant clones become predominant. The characteristics of low-level RAS mutant tumors would be: * Objective response rate (ORR) high (reflecting the sensitive clone) * Progression-free survival (PFS) short (reflecting the more rapid outgrowth of RAS mutant clones)
Details
| Lead sponsor | Ludwig-Maximilians - University of Munich |
|---|---|
| Phase | PHASE2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 120 |
| Start date | Thu Aug 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Aug 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Treatment Related Cancer
Interventions
- Panitumumab
- Irinotecan
- Folinic acid
- 5-FU
Countries
Germany